the real world
Teglutik® – a patented formulation that represents a significant advance using riluzole in ALS1,2
By its nature, riluzole is insoluble in water and causes a strong and persistent anaesthetic effect in the mouth (lasting >20–30 minutes)1 – this is not ideal for administrating as a crushed tablet and is possibly one of the leading causes of unintentional non-adherence* to treatment in ALS.
By enclosing riluzole in a unique liquid-suspension formulation, Teglutik®:1
The development of Teglutik® as an oral suspension represents novelty and innovation, recognised by the international patent granted for its formulation.2